Sanctuary Advisors LLC Acquires 29,581 Shares of Novo Nordisk A/S $NVO

Posted by George Bondi on Jul 18th, 2026

Sanctuary Advisors LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 14.1% during the first quarter, Holdings Channel reports. The fund owned 239,948 shares of the company’s stock after acquiring an additional 29,581 shares during the quarter. Sanctuary Advisors LLC’s holdings in Novo Nordisk A/S were worth $8,818,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Godfrey Financial Associates Inc. bought a new position in Novo Nordisk A/S during the fourth quarter worth $25,000. WealthCollab LLC raised its position in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares during the period. American National Bank & Trust acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $28,000. Maseco LLP bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $29,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: India approved Wegovy for treating MASH, expanding the drug’s potential beyond obesity into fatty liver disease and opening another large growth opportunity. Reuters article
Positive Sentiment: Novo launched oral Wegovy in Europe after winning European Commission approval, giving it the first GLP-1 pill for weight management in the region and strengthening its first-mover advantage. Yahoo Finance article
Positive Sentiment: Reuters reported Novo will launch a lower-cost authorized copy of Ozempic in South Africa, a move that could expand access and support volume growth in an important emerging market. Reuters article
Neutral Sentiment: Analysts at Erste Group trimmed FY2026 EPS estimates slightly to $3.22 from $3.23, a minor cut that does not materially change the current outlook but signals some caution. MarketBeat article
Neutral Sentiment: Brokerages continue to rate Novo Nordisk around “Hold,” suggesting the recent rally is being met with a more balanced valuation view. American Banking News article
Negative Sentiment: Some commentary notes that Eli Lilly still has a chance to win parts of the GLP-1 market, highlighting competitive risk even as Novo’s pill gains traction. The Motley Fool article

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Wolfe Research began coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating for the company. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Finally, Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Five equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and an average target price of $65.56.

Read Our Latest Stock Report on Novo Nordisk A/S

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $50.29 on Friday. The firm has a 50-day moving average price of $46.09 and a two-hundred day moving average price of $45.83. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $71.79. The company has a market capitalization of $224.56 billion, a P/E ratio of 11.81, a P/E/G ratio of 4.70 and a beta of 0.77. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion for the quarter. Analysts anticipate that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

Novo Nordisk A/S Profile

(Free Report)

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.